Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3943 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Innovive commences phase I trial in leukemia

The study will investigate the safety, tolerability, pharmacokinetics and preliminary efficacy of INNO-406 in adult patients with Gleevec-resistant or intolerant Philadelphia positive (Ph+) leukemia or relapsed/refractory Ph+ acute

FDA approves Lilly’s Gemzar in ovarian cancer

Gemzar, which is already approved in lung, pancreatic and breast cancer, generated sales of $1.3 billion last year, making it Lilly’s second best-selling drug. In the latest approval,

Tigris licenses anticancer compound from NIH

AFP-464 (aminoflavone pro-drug) is a novel anticancer agent currently being investigated in two phase I clinical trials sponsored by the National Cancer Institute (“NCI”) in patients with solid

BioLineRx acquires anti-obesity compound

BL-3020 is a peptide that reduces food intake by binding to specific receptors in the brain that control appetite. In contrast to most peptide-based drugs, it has been

Cytori stem cells show promise in heart disease

In this blinded, randomized study, seven pigs received their own adipose stem and regenerative cells (treated) or a saline injection. Autologous adipose stem and regenerative cells were extracted

Alnylam and Inex accelerate RNAi collaboration

Alnylam and Inex formed the collaboration in March 2006. The results to date encourage both parties to believe that Alnylam’s RNAi therapeutics can be efficiently encapsulated in Inex’s